One Hit Thunder

Geekscape

Join musician Chris Fafalios (Punchline) and co-host Matt Kelly from the Geekscape network on One Hit Thunder, where each week they dive into the world of one-hit wonders with a new guest. Chris and Matt are joined by a revolving door of friends, including Chris's bandmates, musicians he’s toured with, and fellow artists, to listen to a one-hit wonder and explore the full catalog of the band or artist behind it. With a mix of humor and musical insight, Chris and Matt dive deep to decide if these artists truly brought the "one hit thunder" and deserved more recognition or if they’re just a "one hit blunder." Perfect for music fans and pop culture enthusiasts alike, One Hit Thunder is a fun and thoughtful exploration of the highs and lows of fleeting fame in the music industry.

  1. You Might Also Like: Science Will Win

    6 HR AGO · BONUS

    You Might Also Like: Science Will Win

    Introducing Bringing Cancer Into Focus: Biomarkers & Precision Medicine from Science Will Win. Follow the show: Science Will Win What if the key to treating cancer was hiding in plain sight – written into its DNA? In this episode of Science Will Win, host Dr. Raven Baxter explores one of the most exciting breakthroughs in cancer care today: the discovery of biomarkers. These tiny molecular signals are helping doctors understand what’s really driving an individual person’s cancer – and opening the door to treatments that can dramatically change patient outcomes. You’ll hear powerful stories from people whose cancers were traced back to a specific biomarker, alongside experts who break down what biomarker testing is, how it works, and why it’s transforming the way we think about cancer treatment.    Biomarkers are showing us that when we understand cancer at its molecular level, a disease that once felt like an unsolvable mystery starts to come into focus. Featured guests: – Dr. Ross Camidge, Director of Thoracic Oncology, University of Colorado – Kelly Huffman, Lung Cancer Patient and Retail Account Manager, Pfizer – Karin Tollefson, Chief Oncology Medical Officer, Pfizer Dive into the episode here: 00:00 – An oncologist’s diagnosis introduces the world of biomarker 03:10 – Defining biomarkers and its history 06:24 – Discovery of the first lung cancer biomarker 08:39 – The start Kelly’s lung cancer journey 16:00 – Biomarkers: how do you test for them? 19:11– Discovery of ALK biomarker shift’s Kelly’s story 22:34 – Landscape of targeted therapy and lung cancer today 25:24 – Moving forward with targeted treatments and conclusion Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Kelly Huffman on her lung cancer journey. Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. DISCLAIMER: Please note, this is an independent podcast episode not affiliated with, endorsed by, or produced in conjunction with the host podcast feed or any of its media entities. The views and opinions expressed in this episode are solely those of the creators and guests. For any concerns, please reach out to team@podroll.fm.

About

Join musician Chris Fafalios (Punchline) and co-host Matt Kelly from the Geekscape network on One Hit Thunder, where each week they dive into the world of one-hit wonders with a new guest. Chris and Matt are joined by a revolving door of friends, including Chris's bandmates, musicians he’s toured with, and fellow artists, to listen to a one-hit wonder and explore the full catalog of the band or artist behind it. With a mix of humor and musical insight, Chris and Matt dive deep to decide if these artists truly brought the "one hit thunder" and deserved more recognition or if they’re just a "one hit blunder." Perfect for music fans and pop culture enthusiasts alike, One Hit Thunder is a fun and thoughtful exploration of the highs and lows of fleeting fame in the music industry.

You Might Also Like